Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in plasma cells | 0.75 |
| chemistry Open Targets | reachable by antibody: peginterferon alfa-2a, albinterferon alfa-2b, peginterferon alfa-2b +8 | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 5 pathways; mostly immune signalling | 0.90 |
Knock down and overexpress IFNAR2 in oligodendrocytes; measure IL-1β and TNF release and surface HLA-DR and α-synuclein uptake and myelin basic protein output under oxidative stress.
- Cell type
- oligodendrocytes
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- IL-1β and TNF release and surface HLA-DR
- Functional readout
- α-synuclein uptake and myelin basic protein output under oxidative stress
- Rule-out
- If neither arm moves IL-1β by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of IFNAR2 in iPSC-derived oligodendrocytes; n = 3 differentiations; readouts: IL-1β and TNF release and surface HLA-DR; α-synuclein uptake and myelin basic protein output under oxidative stress. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- IFNAR2 in dopamine neurons, braakn/a → n/areceipt 16087
- IFNAR2 in oligodendrocytes, braak+0.08 (p 0.838) → +0.64 (p 0.063)receipt 16086
Swarm cases
receipt 16087: IFNAR2 in dopamine neurons, braak
- cell type
- IFNAR2 is not measured in dopamine neurons; looking elsewhere.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IFNAR2 in dopamine neurons.
case closed: nothing better to follow up.
receipt 16086: IFNAR2 in oligodendrocytes, braak
- power
- full sample +0.21 (p 0.403, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.19 (p 0.455, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.08 (p 0.767, n 18). could be the mix.
- skeptic
- leave-one-out range +0.12 to +0.36, sign flips 0; without severely affected donors +0.21 (p 0.403, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IFNAR2 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts